Metabolism-driven Immune Escape Defines Therapeutic Vulnerability in Type I and Type II Ovarian Cancer

Area of Science:

• Oncology
• Immunology
• Metabolic Research

Background:

• Ovarian cancer is a complex disease with varied responses to immunotherapy.
• Metabolic reprogramming significantly influences the tumor immune microenvironment.
• Understanding subtype-specific metabolism is crucial for improving ovarian cancer treatment.

Purpose of the Study:

• To review how metabolic programs in Type I and Type II ovarian cancer impact immune escape.
• To explore the implications of these metabolic differences for immunotherapy.
• To identify potential therapeutic vulnerabilities and combination strategies.

Main Methods:

• Selective literature search of PubMed and Scopus (past decade).
• Analysis of original and review articles on ovarian cancer metabolism, immunology, and immunotherapy.
• Integration of findings on metabolic pathways, immune evasion, and therapeutic strategies.

Main Results:

• Type I ovarian cancer: Glycolysis-dominant, ARID1A loss, PI3K/AKT/mTOR activation, leading to immune suppression but preserved infiltration.
• Type II ovarian cancer: Lipid metabolism-dependent, adipocyte niche adaptation, resulting in immune exclusion and resistance to cytotoxicity.
• Metabolic profiles critically influence response to immune checkpoint inhibitors.

Conclusions:

• Metabolic reprogramming is key to immune escape and immunotherapy response in ovarian cancer.
• Distinct metabolic-immune landscapes of Type I and Type II tumors necessitate subtype-specific strategies.
• Integrating metabolic targeting with immune modulation may improve outcomes and overcome resistance.